tiprankstipranks
Blurbs

Singular Genomics Systems (OMIC) was downgraded to a Hold Rating at J.P. Morgan

Singular Genomics Systems (OMICResearch Report) received a Hold rating and price target from J.P. Morgan analyst Julia Qin yesterday. The company’s shares closed yesterday at $2.72.

Qin covers the Healthcare sector, focusing on stocks such as Invitae, Seer, and Singular Genomics Systems. According to TipRanks, Qin has an average return of 7.3% and a 55.00% success rate on recommended stocks.

Singular Genomics Systems has an analyst consensus of Hold, with a price target consensus of $3.67, implying a 34.93% upside from current levels. In a report released on August 17, UBS also downgraded the stock to a Hold with a $4.50 price target.

See today’s best-performing stocks on TipRanks >>

OMIC market cap is currently $193.6M and has a P/E ratio of -2.33.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OMIC in relation to earlier this year. Last month, David L. Barker, a Director at OMIC bought 60,000.00 shares for a total of $37,800.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Integrated Solution is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Read More on OMIC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles